Apigenin for COVID-19
Apigenin has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z ,
Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588 ,
Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2) ,
Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125 ,
Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.